The study for prevalence of colorectal tumor among duodenal tumor patients

Prospective exploratory study about adenoma detection rate in patients with duodenal epithelial neoplasia - D-CAD study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038749

Enrollment

180

Registered

2019-12-02

Start date

2019-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal tumor, duodenal epithelial tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: <DET group> The patient has been treated their DET by endoscopy (EMR, ESD, EP) or are scheduled to treat their DET in the future, who have not undergone colonoscopy until now, or who have passed 3 or more years since the previous colonoscopy. <Medical checkup group> The patient who undergone a colonoscopy at our hospital's medical dock, and it has passed 3 years or more after the examination.

Exclusion criteria

Exclusion criteria: 1) The patient with family adenomatous polyposis and hereditary non-polyposis colorectal cancer 2) The patient with inflammatory bowel disease 3) The patient who has a history of colon surgery 4) The patient with abnormal blood coagulation function, or the patient who are unable to manage anticoagulant/platelet drugs according to the gastrointestinal endoscopy guidelines 5)Case of vital organ failure 6)The case judged by the attending physician as inappropriate for registration

Design outcomes

Primary

Measure	Time frame
The colorectal adenoma detection rate (ADR) in patients with duodenal epithelial neoplasia and with medical checkup	—

Secondary

Measure	Time frame
1) The ADR for each mucous phenotype (gastric type/intestinal type) in patients with DET 2) The polype detection rat (PDR) in patients with DET and with medical checkup, the PDR for each mucous phenotype (gastric type/intestinal type) in patients with DET 3) The percentage of advanced neoplasia (ex, adenoma over 10mm, adenoma with severe atypia, villous adenoma or adenocarcinoma) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 4) The percentage of colorectal cancer including advanced cancer in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 5) The percentage of laterally spreading tumor (LST) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 6) The percentage of sessile serrated adenoma/polyp (SSA/P) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 7) The percentage of sessile serrated adenoma/polyp (SSA/P) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 8) The mean number of colorectal adenoma in patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET 9) The mean number of colorectal polyp in each patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET 10) The mean number of SSA/P in each patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET	—

Measure

Time frame

1) The ADR for each mucous phenotype (gastric type/intestinal type) in patients with DET 2) The polype detection rat (PDR) in patients with DET and with medical checkup, the PDR for each mucous phenotype (gastric type/intestinal type) in patients with DET 3) The percentage of advanced neoplasia (ex, adenoma over 10mm, adenoma with severe atypia, villous adenoma or adenocarcinoma) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 4) The percentage of colorectal cancer including advanced cancer in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 5) The percentage of laterally spreading tumor (LST) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 6) The percentage of sessile serrated adenoma/polyp (SSA/P) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 7) The percentage of sessile serrated adenoma/polyp (SSA/P) in patients with DET and with medical checkup, that percentage for each mucous phenotype (gastric type/intestinal type) in patients with DET 8) The mean number of colorectal adenoma in patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET 9) The mean number of colorectal polyp in each patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET 10) The mean number of SSA/P in each patient with DET and with medical checkup, the mean number of that for each mucous phenotype (gastric type/intestinal type) in patients with DET

—

Countries

Japan

Contacts

Public ContactMari Mizutani

Keio University of medicine Gastroenterology/ Cancer center

marimizutani6@keio.jp0353633437

Outcome results